Eli Lilly and Company (LLY)vsOnconetix Inc (ONCO)
LLY
Eli Lilly and Company
$934.60
+3.07%
HEALTHCARE · Cap: $760.43B
ONCO
Onconetix Inc
$0.64
-8.57%
HEALTHCARE · Cap: $514,220
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 7993694% more annual revenue ($65.18B vs $815,370). LLY leads profitability with a 31.7% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
ONCO
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+63.4%
Fair Value
$5.05
Current Price
$0.64
$4.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -115.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : ONCO
The strongest argument for ONCO centers on Price/Book, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : ONCO
The primary concerns for ONCO are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while ONCO is a value play — different risk/reward profiles.
ONCO carries more volatility with a beta of 3.63 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 33/100), backed by strong 31.7% margins and 42.6% revenue growth. ONCO offers better value entry with a 63.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Onconetix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Onconetix Inc. is a leading biotechnology company at the forefront of revolutionizing cancer care through innovative diagnostic and therapeutic solutions. Utilizing a proprietary technology platform, the firm emphasizes early detection and personalized treatment approaches for a range of malignancies, aiming to fulfill a vital need in oncology. With a strong and diverse pipeline, Onconetix is strategically positioned to address the rising demand for effective cancer therapies, significantly improving patient outcomes through its advanced research and development efforts in the dynamic landscape of cancer treatment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?